Dallas TX – Sept. 28, 2026 – VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant testing technologies designed to identify unsuccessful drug candidates earlier, potentially improving the economics of pharmaceutical development.
With an industry clinical-trial success rate of approximately 8%, the effective cost of producing one approved medicine includes the expense of numerous failed programs. Identifying toxicity or other biological problems earlier could help drug developers avoid committing substantial capital to candidates unlikely to succeed.
VivoSim’s engineered human liver and intestinal tissues provide researchers with additional evidence before drugs enter expensive clinical programs. The technology may also help determine whether a concerning result from an animal study is species-specific or relevant to humans.
Alongside VivoSim Labs Inc. (NASDAQ: VIVS), investors are also watching KNOREX Ltd. (NYSE: KNRX), Game Your Game, Inc. (NASDAQ: GYGY), Volato Group, Inc. (NYSE: SOAR), Accuray Inc (NASDAQ: ARAY), Fusemachines Inc. (NASDAQ: FUSE) and IGC Pharma, Inc. (NYSE: IGC), as all are seeing active trading today.
The platform’s commercial potential is highlighted by VivoSim’s relationship with Eli Lilly and Company (NYSE: LLY). VivoSim received a $5 million milestone payment related to a divested FXR program acquired by Lilly and may be eligible for up to $45 million in additional milestone payments.
VivoSim’s approach also aligns with the FDA’s growing support for New Approach Methodologies, including human-derived tissues and computational models. As adoption expands, VivoSim could help pharmaceutical companies improve predictions while reducing the time and money lost to unsuccessful drug candidates.
About the Companies
VivoSim Labs Inc. (NASDAQ: VIVS) develops human-relevant 3D tissues and predictive technologies for pharmaceutical discovery, toxicology and preclinical development.
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company focused on discovering and delivering medicines across major therapeutic markets.
About The Street Reports
The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
